Featured Research

from universities, journals, and other organizations

Antibacterial peptide could aid in treating soldiers' burn wound infections

Date:
September 2, 2010
Source:
Temple University
Summary:
An antibacterial peptide looks to be a highly effective therapy against infections in burn or blast wounds suffered by soldiers.

An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple's College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers.

Otvos and his collaborators found that when given intramuscularly the peptide A3-APO was more effective than current antimicrobial chemotherapy measures in treating multidrug-resistant Acinetobacter baumannii, the most common systemic infection found in soldiers who suffer burn or blast wounds. The peptide is also highly efficacious in models of multi-drug resistant systemic Escherichia coli infections.

Their findings are being published in the Journal of Antimicrobial Chemotherapy.

Otvos said that 40 percent of gowns and gloves in military hospitals are infected with Acinetobacter baumannii, and half of the soldiers returning from Iraq and Afghanistan with burn wounds will become infected.

Currently, these infections are treated with an antibiotic, either imipenem or colistin. However, both of these rapidly lose efficacy due to high rates of antimicrobial resistance. In addition, colistin is a strongly toxic drug and worldwide research is focusing on its replacement options.

For their study, the researchers used a strain of Acinetobacter baumannii isolated from an injured Canadian soldier returning from Afghanistan for testing in the lab. They found that A3-APO, when given intramuscularly, was less toxic and more effective in reducing bacterial counts in the blood and the injury site than imipenem or colistin. The peptide also protected open wounds from environmental bacterial infection.

"This is the first peptide ever that is more efficacious in an animal model than anything else that is available," said Otvos, who hopes the peptide can be tested in clinical trials in the near future.


Story Source:

The above story is based on materials provided by Temple University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Eszter Ostorhazi, Ferenc Rozgonyi, Andras Sztodola, Ferenc Harmos, Ilona Kovalszky, Dora Szabo, Daniel Knappe, Ralf Hoffmann, Marco Cassone, John D. Wade, Robert A. Bonomo, and Laszlo Otvos Jr. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections. Journal of Antimicrobial Chemotherapy, 2010; DOI: 10.1093/jac/dkq337

Cite This Page:

Temple University. "Antibacterial peptide could aid in treating soldiers' burn wound infections." ScienceDaily. ScienceDaily, 2 September 2010. <www.sciencedaily.com/releases/2010/09/100901072904.htm>.
Temple University. (2010, September 2). Antibacterial peptide could aid in treating soldiers' burn wound infections. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/09/100901072904.htm
Temple University. "Antibacterial peptide could aid in treating soldiers' burn wound infections." ScienceDaily. www.sciencedaily.com/releases/2010/09/100901072904.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins